Literature DB >> 1688889

Human fibroblasts maintain the viability and augment the functional response of human neutrophils in culture.

C J Ling1, W F Owen, K F Austen.   

Abstract

When human neutrophils were co-cultured for 72 h with nontransformed human fibroblasts, 69 +/- 3% (n = 13) survived, as compared with survival levels of 2 +/- 1% (n = 15) and 26 +/- 6% (n = 7), respectively, for neutrophils cultured for the same time period in enriched medium alone or supplemented with 10 pM recombinant human granulocyte/macrophage colony-stimulating factor (rh GM-CSF). Conditioned medium from the human fibroblast cultures enhanced neutrophil survival in a dose-dependent fashion to the same level achieved with neutrophil/fibroblast co-cultures, and its soluble viability-sustaining activity was not inhibited by preincubation with neutralizing antiserum against rh GM-CSF. As compared with freshly isolated replicate samples, neutrophils co-cultured with human fibroblasts for 72 h exhibited augmented FMLP-stimulated superoxide production without spontaneous superoxide generation. This striking extension of survival and associated priming for a ligand response by neutrophils co-cultured with human fibroblasts suggests that fibroblasts may contribute to the proinflammatory properties of neutrophils in tissues.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1688889      PMCID: PMC296466          DOI: 10.1172/JCI114480

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  15 in total

Review 1.  THE KINETICS OF GRANULOPOIESIS IN NORMAL MAN.

Authors:  G E CARTWRIGHT; J W ATHENS; M M WINTROBE
Journal:  Blood       Date:  1964-12       Impact factor: 22.113

2.  The physiology of granulocytic cells in normal and leukemic states.

Authors:  C G CRADDOCK
Journal:  Am J Med       Date:  1960-05       Impact factor: 4.965

3.  Isolation of mononuclear cells and granulocytes from human blood. Isolation of monuclear cells by one centrifugation, and of granulocytes by combining centrifugation and sedimentation at 1 g.

Authors:  A Böyum
Journal:  Scand J Clin Lab Invest Suppl       Date:  1968

4.  Purified human granulocyte-macrophage colony-stimulating factor: direct action on neutrophils.

Authors:  J C Gasson; R H Weisbart; S E Kaufman; S C Clark; R M Hewick; G G Wong; D W Golde
Journal:  Science       Date:  1984-12-14       Impact factor: 47.728

5.  Recombinant human granulocyte colony-stimulating factor repairs the abnormalities of neutrophils in patients with myelodysplastic syndromes and chronic myelogenous leukemia.

Authors:  A Yuo; S Kitagawa; T Okabe; A Urabe; Y Komatsu; S Itoh; F Takaku
Journal:  Blood       Date:  1987-08       Impact factor: 22.113

6.  Recombinant human granulocyte-macrophage colony-stimulating factor stimulates in vitro mature human neutrophil and eosinophil function, surface receptor expression, and survival.

Authors:  A F Lopez; D J Williamson; J R Gamble; C G Begley; J M Harlan; S J Klebanoff; A Waltersdorph; G Wong; S C Clark; M A Vadas
Journal:  J Clin Invest       Date:  1986-11       Impact factor: 14.808

7.  Human granulocyte-macrophage colony-stimulating factor is a neutrophil activator.

Authors:  R H Weisbart; D W Golde; S C Clark; G G Wong; J C Gasson
Journal:  Nature       Date:  1985 Mar 28-Apr 3       Impact factor: 49.962

8.  Human eosinophils have prolonged survival, enhanced functional properties, and become hypodense when exposed to human interleukin 3.

Authors:  M E Rothenberg; W F Owen; D S Silberstein; J Woods; R J Soberman; K F Austen; R L Stevens
Journal:  J Clin Invest       Date:  1988-06       Impact factor: 14.808

9.  Interleukin 1 stimulates fibroblasts to produce granulocyte-macrophage colony-stimulating activity and prostaglandin E2.

Authors:  J R Zucali; C A Dinarello; D J Oblon; M A Gross; L Anderson; R S Weiner
Journal:  J Clin Invest       Date:  1986-06       Impact factor: 14.808

10.  Clonotypic heterogeneity in experimental interstitial nephritis. Restricted specificity of the anti-tubular basement membrane B cell repertoire is associated with a disease-modifying crossreactive idiotype.

Authors:  M D Clayman; M J Sun; L Michaud; J Brill-Dashoff; R Riblet; E G Neilson
Journal:  J Exp Med       Date:  1988-04-01       Impact factor: 14.307

View more
  6 in total

1.  Eosinophils altered phenotypically and primed by culture with granulocyte/macrophage colony-stimulating factor and 3T3 fibroblasts generate leukotriene C4 in response to FMLP.

Authors:  W F Owen; J Petersen; K F Austen
Journal:  J Clin Invest       Date:  1991-06       Impact factor: 14.808

2.  Reply: from idiopathic pulmonary fibrosis to cystic fibrosis: got lactate?

Authors:  Robert Kottmann; Richard Phipps; Patricia Sime
Journal:  Am J Respir Crit Care Med       Date:  2013-07-01       Impact factor: 21.405

3.  Activities of superoxide dismutases and NADPH oxidase in neutrophils obtained from asthmatic and normal donors.

Authors:  B Z Joseph; J M Routes; L Borish
Journal:  Inflammation       Date:  1993-06       Impact factor: 4.092

4.  Differential survival of leukocyte subsets mediated by synovial, bone marrow, and skin fibroblasts: site-specific versus activation-dependent survival of T cells and neutrophils.

Authors:  Andrew Filer; Greg Parsonage; Emily Smith; Chloe Osborne; Andrew M C Thomas; S John Curnow; G Ed Rainger; Karim Raza; Gerard B Nash; Janet Lord; Mike Salmon; Christopher D Buckley
Journal:  Arthritis Rheum       Date:  2006-07

5.  Antioxidant, anti-inflammatory, anti-apoptotic, and skin regenerative properties of an Aloe vera-based extract of Nerium oleander leaves (nae-8(®)).

Authors:  Kathleen F Benson; Robert A Newman; Gitte S Jensen
Journal:  Clin Cosmet Investig Dermatol       Date:  2015-05-06

6.  The significance of low bcl-2 expression by CD45RO T cells in normal individuals and patients with acute viral infections. The role of apoptosis in T cell memory.

Authors:  A N Akbar; N Borthwick; M Salmon; W Gombert; M Bofill; N Shamsadeen; D Pilling; S Pett; J E Grundy; G Janossy
Journal:  J Exp Med       Date:  1993-08-01       Impact factor: 14.307

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.